Anti-TSG101 antibody produced in rabbit
SIGMA/AV38773 - IgG fraction of antiserum
Synonym: Anti-Ttumor susceptibility gene 101
Product Type: Chemical
Immunoblotting Cell Type: HepG2 (Cat. No. AV38773). Lanes 1. Antibody dilution (concentration) 2.5 μg/mL in cell type HepG2
Western Blotting Western Blot of TSG101 in Rat Brain with TSG101 antibody at 1 μg/mL
| antibody form | IgG fraction of antiserum |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | polyclonal |
| concentration | 0.5 mg - 1 mg/mL |
| conjugate | unconjugated |
| form | buffered aqueous solution |
| mol wt | 44 kDa |
| NCBI accession no. | NP_006283   |
| Quality Level | 100 |
| shipped in | wet ice |
| species reactivity | human, horse, dog, rabbit, guinea pig, bovine, rat, goat, mouse |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | western blot: suitable |
| UniProt accession no. | Q99816 |
| Biochem/physiol Actions: | TSG101 belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. TSG101 contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. TSG101 may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of TSG101 appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in TSG101 gene occur in high frequency in breast cancer. The protein encoded by this gene belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. The gene product contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. The protein may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of this tumor susceptibility gene appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in this gene occur in high frequency in breast cancer and suggest that defects occur during breast cancer tumorigenesis and/or progression. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| Immunogen: | Synthetic peptide directed towards the C terminal region of human TSG101 |
| Physical form: | Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
| Sequence: | Synthetic peptide located within the following region: TIFYLGEALRRGVIDLDVFLKHVRL |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |